Malignant Neuroendocrine Tumors: Incidence and Outcomes in Pediatric Patients

 

 Buy Article Permissions and Reprints

Abstract

Introduction Malignant neuroendocrine tumors (NETs) are rare solid tumors infrequently seen in children. This study examines current incidence trends and outcomes for children with NETs.

Materials and Methods The Surveillance Epidemiology and End Results registry was examined for patients between birth and 19 years of age between 1973 and 2005 with NETs.

Results Overall, 481 patients were identified with malignant NETs. Tumors were classified as malignant carcinoid (n = 189, 39%), central nervous system tumors (n = 127, 26%), medullary thyroid carcinoma (n = 88, 18%), neuroendocrine carcinoma (n = 50, 10%), pheochromocytoma (n = 17, 3.5%), and paraganglioma (n = 7, 1.5%). Children less than 5 years of age had worse 5-year survival ( < 50 vs. > 76% if older, p = 0.009). Blacks had lower 5-year survival compared with whites (61 vs. 81%, p = 0.001). Tumor locations with favorable prognosis included the appendix, lung, and thyroid ( > 95% 5-year survival), whereas soft tissue and ovary location were associated with poor survival (p < 0.001). In multivariate analysis, distant disease at diagnosis (odds ratio [OR] 14.9; 95% confidence interval [CI], 6.9 to 32.1) and black race (OR 3.3; 95% CI, 1.4 to 7.4) were independent predictors of death.

Conclusion Whites have the highest incidence of pediatric NETs. Colon/rectum, appendix, or thyroid tumor location portends favorable prognosis. Black children and those less than 5 years of age had poorer prognosis.

• References

• 1 Rosai J. The origin of neuroendocrine tumors and the neural crest saga. Mod Pathol 2011; 24 (Suppl. 02) S53-S57
  CrossrefPubMedGoogle Scholar
• 2 Rindi G, Villanacci V, Ubiali A, Scarpa A. Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn 2001; 1 (3) 323-333
  CrossrefPubMedGoogle Scholar
• 3 Rindi G, Bordi C. Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer 2003; 10 (4) 427-436
  CrossrefPubMedGoogle Scholar
• 4 Sarvida ME, O'Dorisio MS. Neuroendocrine tumors in children and young adults: rare or not so rare. Endocrinol Metab Clin North Am 2011; 40 (1) 65-80 , vii
  CrossrefPubMedGoogle Scholar
• 5 Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25 (3) 458-511
  CrossrefPubMedGoogle Scholar
• 6 Navalkele P, O'Dorisio MS, O'Dorisio TM, Zamba GK, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer 2011; 56 (1) 50-57
  CrossrefPubMedGoogle Scholar
• 7 Surveillance Epidemeology and End Results (SEER) Program. Available at http://www.seer.cancer.gov . Released April 2008. Accessed November 18, 2009
  PubMedGoogle Scholar
• 8 Liu L, Krailo M, Reaman GH, Bernstein L. Surveillance, Epidemiology and End Results Childhood Cancer Linkage Group. Childhood cancer patients' access to cooperative group cancer programs: a population-based study. Cancer 2003; 97 (5) 1339-1345
  CrossrefPubMedGoogle Scholar
• 9 Gutierrez JC, Fischer AC, Sola JE, Perez EA, Koniaris LG. Markedly improving survival of neuroblastoma: a 30-year analysis of 1,646 patients. Pediatr Surg Int 2007; 23 (7) 637-646
  CrossrefPubMedGoogle Scholar
• 10 Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res 2009; 156 (1) 167-172
  CrossrefPubMedGoogle Scholar
• 11 Kassira N, Pedroso FE, Cheung MC, Koniaris LG, Sola JE. Primary gastrointestinal tract lymphoma in the pediatric patient: review of 265 patients from the SEER registry. J Pediatr Surg 2011; 46 (10) 1956-1964
  CrossrefPubMedGoogle Scholar
• 12 Neville HL, Hogan AR, Zhuge Y , et al. Incidence and outcomes of malignant pediatric lung neoplasms. J Surg Res 2009; 156 (2) 224-230
  CrossrefPubMedGoogle Scholar
• 13 Perez EA, Gutierrez JC, Koniaris LG, Neville HL, Thompson WR, Sola JE. Malignant pancreatic tumors: incidence and outcome in 58 pediatric patients. J Pediatr Surg 2009; 44 (1) 197-203
  CrossrefPubMedGoogle Scholar
• 14 Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE. Rhabdomyosarcoma in children: a SEER population based study. J Surg Res 2011; 170 (2) e243-e251
  CrossrefPubMedGoogle Scholar
• 15 Klimstra DS, Modlin IR, Adsay NV , et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010; 34 (3) 300-313
  CrossrefPubMedGoogle Scholar
• 16 Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39 (6) 707-712
  CrossrefPubMedGoogle Scholar
• 17 Yao JC, Hassan M, Phan A , et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
  CrossrefPubMedGoogle Scholar
• 18 Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer 2008; 123 (4) 867-873
  CrossrefPubMedGoogle Scholar
• 19 Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17 (4) 959-965
  CrossrefPubMedGoogle Scholar
• 20 Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113 (1) 5-21
  CrossrefPubMedGoogle Scholar
• 21 Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21 (1) 15-31
  CrossrefPubMedGoogle Scholar
• 22 Klöppel G, Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2005; 19 (4) 507-517
  CrossrefPubMedGoogle Scholar
• 23 Hauso O, Gustafsson BI, Kidd M , et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113 (10) 2655-2664
  CrossrefPubMedGoogle Scholar
• 24 Khanna G, O'Dorisio SM, Menda Y, Kirby P, Kao S, Sato Y. Gastroenteropancreatic neuroendocrine tumors in children and young adults. Pediatr Radiol 2008; 38 (3) 251-259 , quiz 358–359
  PubMedGoogle Scholar
• 25 Parham DM. Neuroectodermal and neuroendocrine tumors principally seen in children. Am J Clin Pathol 2001; 115 (Suppl): S113-S128
  PubMedGoogle Scholar
• 26 Hörsch D, Grabowski P, Schneider CP , et al. Current treatment options for neuroendocrine tumors. Drugs Today (Barc) 2011; 47 (10) 773-786
  PubMedGoogle Scholar
• 27 Kim SJ, Kim JW, Han SW , et al. Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer 2010; 10: 448
  CrossrefPubMedGoogle Scholar